Bio-Rad Laboratories Inc (Bio-Rad) manufactures and distributes life science research and clinical diagnostics products. The company's product portfolio includes antibodies, autoimmune testing kits, blood typing and antibody detection systems, cell isolation and analysis tools, and digital PCR, among others. The company serves to various markets including life science research, healthcare, analytical chemistry, and other markets. Bio-Rad’s products find applications in bioprocess analytics, cell research, gene expression analysis, immunology, and mutation detection, among others. It markets products through a direct sales force and a network of distributors, agents, brokers, and resellers worldwide. The company operates in the US, Canada, Latin America, Europe and Asia, among others. Bio-Rad Laboratories Inc is headquartered in Hercules, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Bio-Rad Laboratories Inc
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Bio-Rad Laboratories Inc Company Overview
Bio-Rad Laboratories Inc Company Snapshot
Bio-Rad Laboratories Inc Pipeline Products and Ongoing Clinical Trials Overview
Bio-Rad Laboratories Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Bio-Rad Laboratories Inc, Recent Developments
May 22, 2024: GCCL Leverages ddPCR to Enhance Gene/cell Therapy Clinical Trial Services
Apr 11, 2024: Bio-Rad and Allegheny Health Network Cancer Institute Partner to Advance Personalized Monitoring of Solid Tumor Cancers with Droplet Digital PCR
Apr 03, 2024: Bio-Rad Launches First Ultrasensitive Multiplexed Digital PCR Assay for Breast Cancer Mutation Detection in Clinical Research
Apr 01, 2024: Bio-Rad Launches First Ultrasensitive Multiplexed Digital PCR Assay for Breast Cancer Mutation Detection in Clinical Research
Mar 26, 2024: Bio-Rad Launches Celselect Slides Validated Antibodies for Rare Cell and Circulating Tumor Cell Enumeration
Feb 27, 2024: Bio-Rad Launches Vericheck ddPCR Replication Competent Lentivirus and Replication Competent AAV Kits for Cell and Gene Therapy Production
Jan 02, 2024: Bio-Rad’s Management to Host Investor Meetings at J.P. Morgan’s 42nd Annual Healthcare Conference
Oct 05, 2023: Bio-Rad Extends Range of Anti-Idiotypic Antibodies for Use in Preclinical and Clinical Drug Development
Sep 28, 2023: Bio-Rad Launches PTC Tempo 48/48 and PTC Tempo 384 Thermal Cyclers
Aug 29, 2023: Bio-Rad Launches First StarBright Red Dye and Extends Range of Antibody Markers Conjugated to StarBright Dyes to Enhance Multiplex Flow Cytometry and Research Capabilities